Current Report Filing (8-k)
April 25 2016 - 7:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
April 22, 2016
AKERS
BIOSCIENCES, INC.
(Exact
name of registrant as specified in its charter)
New
Jersey
|
|
333-190456
|
|
22-2983783
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
201
Grove Road
Thorofare,
NJ 080086
(Address
of Principal Executive Offices)
(856)
848-2116
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
Resignation
of Executive Chairman
On
April 22, 2016, Dr. Raymond F. Akers, Jr., PhD, delivered a letter of resignation (the “Resignation Letter”) to the
Board of Directors (the “Board”) of Akers Biosciences, Inc. (the “Company”), resigning from his position
as Executive Chairman and Co-Chairman of the Board of the Company, effective immediately. Dr. Akers will continue to serve as
a director of the Company.
Appointment
of Chairman of the Board
Effective
April 22, 2016, the Board appointed Thomas Knox, current Co-Chairman of the Board, as the sole Chairman of the Board.
Appointment
of Co-Founder/Chief Scientific Director
On
April 22, 2016, the Company appointed Dr. Raymond F. Akers, Jr., PhD as Co-Founder/Chief Scientific Director of the Company. Dr.
Akers will be entitled to an annual base salary of $200,000 and will be eligible to receive performance bonuses at the sole discretion
of the Board.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AKERS
BIOSCIENCES, INC.
|
|
|
|
Date:
April 25, 2016
|
By:
|
/s/
John Gormally
|
|
|
John
Gormally
|
|
|
Chief
Executive Officer
|
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jun 2024 to Jul 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2023 to Jul 2024